Blockchain Registration Transaction Record

Blood Pressure Drug Shows Promise Against Aggressive Brain Cancer

Researchers discover common blood pressure drug hydralazine may slow aggressive glioblastoma growth. Breakthrough reveals novel mechanism for treating brain cancer with existing medication.

This discovery matters because glioblastoma is one of the most aggressive and difficult-to-treat brain cancers, with limited treatment options and poor survival rates. The potential repurposing of an existing, well-understood medication like hydralazine could significantly accelerate treatment development, potentially providing patients with new therapeutic options much faster than traditional drug development timelines. Given that glioblastoma affects approximately 12,000 people annually in the United States alone and has a median survival of only 15 months even with current treatments, any breakthrough that offers hope for slowing tumor growth represents a crucial advancement in neuro-oncology that could directly impact patient survival and quality of life.